Understanding the molecular basis of immune checkpoint inhibition is transforming the management of metastatic melanoma, and is likely to have a major impact on other cancers ([@bib9]). Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to potentiate anti-tumour T-cell responses, has been shown to prolong overall survival ([@bib10]; [@bib18]), with a proportion of patients surviving beyond 5 years ([@bib20]). The main toxicity seen with ipilimumab is related to activation of the immune system against autoantigens. Grade 3--4 immune-related adverse events (irAEs) occur in 10%--15% of patients: primarily skin rash, diarrhoea and colitis, hepatitis and endocrinopathies ([@bib10]; [@bib18]). Ipilimumab is approved by regulatory authorities for the first- and subsequent-line treatment of metastatic melanoma.

The programmed cell death 1 (PD-1) receptor negatively regulates the effector phase of T-cell responses after binding to PD-L1, which is frequently expressed on tumour cells and in the tumour microenvironment ([@bib19]). Antibodies blocking this interaction release the cytotoxic potential of tumour-specific T-cells. Pembrolizumab and nivolumab, monoclonal antibodies that bind the PD-1 receptor, have demonstrated significant and durable tumour responses with manageable toxicity profiles ([@bib9]; [@bib22]; [@bib16]).

Two recent phase III studies have reported the superiority of both pembrolizumab and nivolumab to ipilimumab in patients with advanced melanoma as first-line therapy ([@bib14]; [@bib17]). The Keynote 006 study (NCT01866319) randomised 834 patients in a 1 : 1 : 1 ratio to receive ipilimumab or two dosing schedules of pembrolizumab. The estimated 6-month progression-free survival (PFS) rate was significantly higher for both pembrolizumab arms as compared with ipilimumab (47.3%, 46.4%, 26.5%, respectively) with estimated 12-month overall survival rates of 74.1%, 68.4%, 58.2%, respectively ([@bib17]). The Checkmate 067 study (NCT01844505) evaluated nivolumab or nivolumab plus ipilimumab *vs* ipilimumab alone in 945 patients with previously untreated advanced melanoma. Progression-free survival was significantly longer for nivolumab alone or combined with ipilimumab compared with ipilimumab alone (6.9 months, 11.5 months, 2.9 months, respectively) and objective response rates higher (43.7%, 57.6%, 19.0%, respectively; [@bib14]). On the basis of these results, anti-PD-1 antibodies represent a new standard of care in the first-line treatment of patients with advanced melanoma.

Combination immunotherapy with nivolumab and ipilimumab is associated with higher objective response rates and PFS compared with monotherapy ipilimumab. Combination therapy, however, is associated with significant toxicity with greater than half of patients experiencing grade 3 or 4 adverse events ([@bib14]). It is currently unclear whether combined anti-PD-1 antibody with ipilimumab treatment will be widely adopted due to concerns about toxicity but the doublet is currently licensed by the US Food and Drug Administration. In addition, the overall survival data are not yet reported and this study was not designed to compare the combination *vs* nivolumab monotherapy for this end point ([@bib14]). For patients who have progressed on anti-PD-1 therapy, ipilimumab will be a frequent second- or third-line treatment. Currently, there is very limited evidence regarding the efficacy and toxicity of ipilimumab after anti-PD-1 antibodies. We report the clinical efficacy and toxicity profile seen with this therapeutic sequence in the largest retrospective cohort to date.

Materials and Methods
=====================

Patient population
------------------

We retrospectively identified patients with advanced melanoma who had sequentially been treated with the anti-PD-1 antibodies pembrolizumab or nivolumab followed by ipilimumab. Only patients who had received sequential treatment were suitable for inclusion. Cases were identified at eight sites in Australia and two in the United Kingdom. The data collected included: baseline demographics (age, gender), mutational status (BRAF/NRAS) and prognostic variables (American Joint Committee on Cancer (AJCC) stage of disease, lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) performance status); details of the anti-PD-1 inhibitor treatment (type, dosage, number of cycles received and toxicity) and ipilimumab treatment (number of cycles and toxicity); data pertaining to response to respective therapies; time interval between PD-1 inhibitor treatment and commencement of ipilimumab; and time to end point data. Progression-free survival was defined as the time between date of commencement of therapy to date of progression or death. The response assessments were assessed according to response evaluation criteria in solid tumors (RECIST) 1.1 ([@bib7]) and/or immune-related response criteria ([@bib27]). Severity of adverse events was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

The identified patients all accessed anti-PD-1 therapy through clinical trials and the schedule and dose received was as per clinical trial protocol. All the sites had the appropriate ethics approval for the relevant clinical trial. Subsequent ipilimumab treatment was at standard dosing (3 mg kg^−1^ intravenously, three weekly to a maximum of four doses).

Results
=======

Patient demographics and anti-PD-1 therapy
------------------------------------------

A total of 40 patients were identified who received either pembrolizumab or nivolumab followed by ipilimumab between November 2012 and July 2015. The baseline demographic data are detailed in [Table 1](#tbl1){ref-type="table"}, and are consistent with typical melanoma patient populations, except for the low rate of BRAF mutation positivity (10%), likely due to selection/eligibility for anti-PD-1 studies. The majority of patients were males (63%) with AJCC stage M1c disease (85%). All patients had a good performance status before commencement of anti-PD-1 therapy (ECOG 0--1) and 60% had a normal baseline LDH. Thirty-six percent of patients had received other systemic therapy before the commencement of a PD-1 inhibitor. Four (10%) patients had received ipilimumab as a prior therapy and were subsequently rechallenged.

Of the 40 patients identified, 26 (65%) received pembrolizumab at either a dose of 10 mg kg^−1^ on a two or three weekly basis or 2 mg kg^−1^ three weekly and 14 (35%) patients received nivolumab 3 mg kg^−1^ two weekly. All patients discontinued anti-PD 1 inhibitor owing to progression and were treated with ipilimumab as the next line of systemic therapy.

The median treatment duration on anti-PD-1 therapy and median PFS were 5 months. Eight (20%) patients achieved an objective response to anti-PD-1 therapy, 15 (38%) had stable disease and 17 (42%) had progressive disease as their best treatment response ([Table 2](#tbl2){ref-type="table"}). Three (8%) patients developed grade 3/4 irAEs thought attributable to the PD-1 inhibitor ([Table 3](#tbl3){ref-type="table"}).

Efficacy and toxicity of ipilimumab following failure of anti-PD-1 therapy
--------------------------------------------------------------------------

The median follow-up for all patients after commencement of ipilimumab therapy was 12.5 months (range 4--23 months). Four (10%) patients achieved an objective response to ipilimumab, and an additional 3 (8%) experienced prolonged stable disease (greater than 6 months) after completion of their treatment. Thirty-three (82%) patients progressed on therapy ([Table 2](#tbl2){ref-type="table"}). Of the patients who obtained a clinical benefit (objective response or prolonged stable disease \>6 months) from ipilimumab, one (1/17) had previously failed to respond to anti-PD-1 therapy, three patients had stable disease and an additional three had a partial response as their best treatment response to anti-PD-1 therapy. Two patients experiencing a clinical benefit experienced grade 3/4 irAEs. The median interval between the final dose of PD-1 inhibitor therapy and the first dose of ipilimumab was 53 days (range 2--683 days). The median time between the last dose of anti-PD-1 therapy and the commencement of ipilimumab therapy did not significantly differ between patients obtaining a clinical benefit from ipilimumab and non-responders. The median interval between therapies was 32 days for those who experienced toxicity. Only 22 (55%) patients received all the four doses of ipilimumab, with early termination owing to toxicity (30%) and/or clinical deterioration (15%).

Fourteen (35%) patients developed grade 3--5 irAEs associated with ipilimumab therapy ([Table 3](#tbl3){ref-type="table"}). Ten percent of these high-grade irAEs occurred after receiving only one cycle of ipilimumab. No patients who were rechallenged with ipilimumab experienced a high-grade irAE, and only one of the five patients achieved an objective response. The most common high-grade irAE was diarrhoea or colitis (grade 3/4 23%), all requiring immunosuppressive therapies. Other grade 3/4 immune-related toxicities were hepatitis, pneumonitis and a case of encephalitis. Two (5%) patients experienced two grade 3/4 iAEs simultaneously (pneumonitis and hepatitis, diarrhoea and hepatitis), which required multiple lines of immunosuppression before improvement was seen clinically and biochemically. Three (8%) patients developed grade 3--5 pneumonitis, one of whom died ([Figure 1](#fig1){ref-type="fig"}). One patient recovered fully after a prolonged course of high-dose intravenous and oral steroids and the third patient required \>6 months of immunosuppression with oral steroids, mycophenolate and tacrolimus. Two of the 14 (14%) patients who experienced high-grade irAEs with ipilimumab had developed severe irAEs (hypothyroidism, bullous pemphigoid) with previous anti-PD-1 therapy.

Discussion
==========

Recent clinical trials have demonstrated superior efficacy of the anti-PD-1 antibodies pembrolizumab and nivolumab compared with ipilimumab in the front line treatment of patients with advanced melanoma establishing these agents as a new standard of care ([@bib14]; [@bib17]).Thirty to forty-five percent of patients respond to anti-PD-1 therapy with durable responses in the majority. Nevertheless, a significant proportion of patients will require second-line therapy, and ipilimumab is the most likely choice. Although the safety profile for pembrolizumab in ipilimumab naive and pre-treated patients was similar in the KEYNOTE-001 study ([@bib5]), and nivolumab has been tolerated safely as sequential treatment, even after patients have experienced grade 3 toxicity with ipilimumab ([@bib25]; [@bib26]), there is very limited evidence for the reverse treatment sequence.

We report on a large cohort of patients that have received treatment with ipilimumab after failure of anti-PD-1 therapy. Twenty percent of patients initially obtained an objective response to anti-PD-1 therapy, a lower response rate than reported in monotherapy clinical trials. Responses to anti-PD-1 therapy are usually durable; as this patient cohort was retrospectively identified as requiring subsequent ipilimumab, it is expected the response rates would be lower than that in an unselected population. The biology of innate *vs* acquired resistance to anti-PD-1 therapy is likely to be different. Innate resistance to anti-PD-1 therapy, as seen in the majority of this cohort, may be a poor prognostic variable or may indicate that alternate approaches to immune modulation need to be considered.

Twenty percent of patients in our cohort obtained a clinical benefit (response or prolonged stable disease) from ipilimumab therapy in keeping with previous reports in patients who have progressed on anti-PD-1 therapy ([@bib25]). The objective response rate of 10% is similar to the response rates seen with ipilimumab in trials in the first- and second-line setting ([@bib10]; [@bib14]; [@bib17]). However, of patients who progressed through anti-PD-1 inhibitor therapy, only one responded to subsequent ipilimumab. Overall survival data for this cohort is immature. Ipilimumab can induce durable responses in patients who achieve stable disease, as well as those who achieve an objective response making overall survival a more meaningful end point to assess the efficacy of ipilimumab ([@bib20]). The authors acknowledge that response rates alone are insufficient to make conclusions on the efficacy of ipilimumab after failure of anti-PD-1 therapy and further prospective studies are required. However, responses to ipilimumab can be seen even after failure of anti-PD-1 therapy making it a viable treatment option.

An important finding in this analysis is that grade 3/4 immune-related toxicity occurred in over a third of patients treated with sequential ipilimumab following anti-PD-1 therapy, a higher rate than generally observed with the currently approved dose of 3 mg kg^−1^ ipilimumab ([@bib10]; [@bib12]; [@bib17]). Also, increased toxicity did not appear to correlate with improved response rates, unlike previous reports in the literature ([@bib6]). Diarrhoea or colitis were the most common toxicities, followed by hepatitis, consistent with the known toxicity profile of ipilimumab. Gastrointestinal and hepatic toxicity typically develops 6--7 weeks following the commencement of ipilimumab ([@bib24]); however, we encountered early toxicity, as three patients experienced grade 3 diarrhoea after one cycle of ipilimumab. In this cohort, three patients experienced grade 3/4 pneumonitis, and one patient died due to this treatment complication. Pneumonitis has been rarely described with ipilimumab therapy and is more commonly reported in association with PD-1 inhibitors ([@bib23]). Our experience suggests that it is a more frequent irAE encountered with ipilimumab delivered subsequent to anti-PD-1 therapy.

Pharmacokinetic studies have demonstrated that the mean elimination half-life of pembrolizumab is 26 days and 17--25 days for nivolumab, with linear pharmacokinetics ([@bib2]; [@bib15]). In addition, flow cytometry has been used to estimate PD-1 occupancy on circulating T cells over time with nivolumab. Owing to its high affinity, a mean plateau occupancy of 72% was seen for ⩾59 days after a single dose, suggesting that even when serum levels are undetectable sufficient concentrations persist to maintain PD-1 occupancy ([@bib1]). The high rates of toxicity in this group with a median time between treatments of 32 days may indicate that this is not an adequate washout period.

In addition, biomarker studies from a phase I study of nivolumab demonstrated that CTLA-4 positive CD4 T cells were significantly increased in non-responders after treatment which could be a potentiating factor for the excess toxicity seen in this series given that all patients discontinued anti-PD-1 therapy due to progression ([@bib8]).

Translational studies using blood samples collected from patients who have been treated with anti-PD-1 or anti-CTLA-4 agents alone, in combination or sequenced have revealed vastly different T-cell gene expression profiles between these patient cohorts ([@bib4]). This underscores that a combined blockade of co-inhibitory T-cell receptors at the same time can lead to a different immunological outcome than the sequential engagement of the same receptors. A more detailed understanding of such dose, sequence and combinatorial differences on immune and tumour cell function is urgently required to guide selection of the most mechanistically rational immunotherapy regimen. Furthermore, the immunological profile induced by anti-PD-1 pre-treatment may increase the autoimmune potential of T cells that are subsequently activated during anti-CTLA-4 therapy and hence be a mechanism for increased toxicity.

In keeping with our observation of increased toxicity of anti-CTLA-4 blockade after anti-PD-1 treatment, a case series reported on three patients who were treated in the same sequence and experienced prolonged, difficult-to-treat autoimmune colitis ([@bib3]). A further series of patients treated with sequential therapy reported that three out of five patients experienced high-grade irAEs, one of which was encephalopathy in addition to hepatitis ([@bib13]). There is also some suggestion that toxicity of vemurafenib may be potentiated by prior anti-PD-1 therapy ([@bib11]; [@bib13]).

Results of pivotal phase III studies have established PD-1 inhibitors as first-line therapy in advanced melanoma. For those failing anti-PD-1 therapy, ipilimumab will be a treatment option for many patients, as borne out by current clinical practice in patients progressing on PD-1 inhibitors and owing to a lack of effective therapeutic alternatives outside of clinical trials. However, our early experience suggests that the toxicity of ipilimumab given after anti-PD-1 therapy may be greater than is seen in first-line therapy or after other treatments. For the moment, when treating with ipilimumab following failure of PD-1 inhibitors, oncologists should have increased vigilance for severe and potentially early immune-related toxicity.

Many questions remain unanswered surrounding appropriate patient selection and predictive biomarkers for immune checkpoint inhibitors in clinical practice. Greater understanding of the tumour microenvironment and the process of immune-editing is fundamental to allow rational stratification of new immunotherapies and combinations to achieve optimal responses on an individual basis ([@bib21]).
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![**Computer tomography scans demonstrating a severe pneumonitis during ipilimumab therapy; a 61-year-old patient with metastatic melanoma commenced ipilimumab after having progressed several weeks earlier on nivolumab treatment** (**A**). She developed a severe pneumonitis after three doses of ipilimumab (**B**) that resolved on intensified immunosuppression with a prolonged course of high dose intravenous and oral glucocorticoids (**C**).](bjc2016107f1){#fig1}

###### Baseline characteristics before anti-PD-1 therapy

                                                  **Total (%);** ***N*****=40**
  ----------------------------------------------- ----------------------------------
  Age in years, median (range)                    61 (37--79)
  **Sex**                                         
  Female                                          15 (37)
  Male                                            25 (63)
  **Mutational status**                           
  BRAF V600 mutated                               4 (10)
  Wild-type                                       36 (90)
  **AJCC stage**                                  
  M1a                                             2 (5)
  M1b                                             4 (10)
  M1c                                             34 (85)
  **Pre-treated brain metastases at treatment**   
  No                                              37 (92)
  Yes                                             3 (8)
  **ECOG performance status**                     
  0--1                                            40 (100)
  ⩾2                                              0
  **LDH**                                         
  Normal                                          24 (60)
  Elevated                                        16 (40)
  **Prior therapy**                               
  BRAF+/−MEK inhibitor                            3 (7)
  Ipilimumab                                      4 (10)
  Chemotherapy                                    7 (17)
  Other                                           2 (5)[a](#t1-fn2){ref-type="fn"}
  Nil                                             26 (64)

Abbreviations: AJCC=American Joint Committee on Cancer; ECOG=Eastern Cooperative Oncology Group; LDH=lactate dehydrogenase; PD-1=programmed cell death-1.

Nilotinib & lenvatinib.

###### Response to treatment

  **Best overall response**--**no. (%)**   **Pembrolizumab,** ***N*****=26 (65%)** **Nivolumab,** ***N*****=14 (35%)**   **Ipilimumab,** ***N*****=40**
  ---------------------------------------- ----------------------------------------------------------------------------- --------------------------------
  Complete response                        0                                                                             0
  Partial response                         8 (20)                                                                        4 (10)
  Stable disease                           15 (38)                                                                       3 (8)
  Progressive disease                      17 (42)                                                                       33 (82)

###### Severe immune-related adverse events

                             **Pembrolizumab,** ***N*****=26 (65%)** **Nivolumab,** ***N*****=14 (35%)**   **Ipilimumab,** ***N*****=40**
  -------------------------- ----------------------------------------------------------------------------- --------------------------------
  Grade 3/4 irAEs--no. (%)   3 (8)                                                                         14 (35%)
                             Hypothyroidism--1                                                             Colitis/diarrhoea--9
                             Panhypopituitarism--1                                                         Pneumonitis--3
                             Bullous pemphigoid--1                                                         Hepatitis--2
                                                                                                           Encephalitis--1

Abbreviation: irAE=immune-related adverse event.
